logo Creation made simple
Beautifully designed
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut convallis tempor orci vitae vehicula. Aliquam in ullamcorper lacus.
Follow & share
Search:
Infallible Pharma | TIGEFIN / TIGINIF INJECTION
21170
portfolio_page-template-default,single,single-portfolio_page,postid-21170,edgt-core-1.0.1,ajax_fade,page_not_loaded,,hudson-ver-1.8, vertical_menu_with_scroll,smooth_scroll,side_menu_slide_from_right,blog_installed,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

TIGEFIN / TIGINIF INJECTION

TIGEFIN / TIGINIF INJECTION


Brand Name : Tigefin / Tiginif


Generic Name : Tigecycline for Injection USP 50 mg


Pack Size : Vial


Dosage Form : Lyophilized powder for Infusion


Strength : 50 mg


Therapeutic indications : Tigecycline is indicated in adults and in children from the age of eight years for the treatment of the following infections:
Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections;
Complicated intra-abdominal infections (cIAI).
Tigecycline should be used only in situations where other alternative antibiotics are not suitable.
Consideration should be given to official guidance on the appropriate use of antibacterial agents.


Pharmacotherapeutic group : Antibacterials for systemic use, tetracyclines


ATC code : J01AA12


Pharmacodynamic properties : Tigecycline, a glycylcycline antibiotic, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains.
In general, tigecycline is considered bacteriostatic. At 4 times the minimum inhibitory concentration (MIC), a 2-log reduction in colony counts was observed with tigecycline against Enterococcus spp., Staphylococcus aureus, and Escherichia coli.

Date

February 18, 2022

Share